Global At-Home Cancer Testing Market Size, Share, and COVID-19 Impact Analysis, Russia-Ukraine War Impact, Tariff Analysis, By Sample Type (Blood Sample, Saliva Sample, Urine Sample, and Tissue Sample), By Cancer Type (Colon Cancer, Breast Cancer, Prostate Cancer, Blood Cancer, and Others), By Test Type (Genetic Testing, Biomarker Testing, Immunological Testing, and Cell-Free DNA Testing), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035

Global At-Home Cancer Testing Market Size Insights Forecasts to 2035

• The Global At-Home Cancer Testing Market Size Was Estimated at USD 7.3 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 4.30% from 2025 to 2035
• The Worldwide At-Home Cancer Testing Market Size is Expected to Reach USD 11.6 Billion by 2035
• Asia Pacific is expected to Grow the fastest during the forecast period.

According to a Research Report Published by Spherical Insights and Consulting, The Global At-Home Cancer Testing Market Size was worth around USD 7.3 Billion in 2024 and is predicted to Grow to around USD 11.6 Billion by 2035 with a compound annual growth rate (CAGR) of 4.30 % from 2025 to 2035. At-home cancer testing is an example of a rapidly evolving health care model, presenting an opportunity for a company specializing in cancer testing. It is a user-friendly solution for early cancer identification, enabling users to execute testing from the comfort of their homes with reduced need for recurrent, invasive clinic visits. It is anticipated that the consumer's increasing demand for early diagnosis, personalized healthcare, and the convenience of self-testing, will support market growth.

Global At-Home Cancer Testing Market Forecast and Revenue Outlook

• 2024 Market Size: USD 7.3 Billion
• 2035 Projected Market Size: USD 11.6 Billion
• CAGR (2025-2035): 4.30%
• North America: Largest market in 2024
• Asia Pacific: Fastest growing market

Market Overview

The at-home cancer testing market is the industry encompassing the production of user-friendly kits for early cancer detection, screening, and monitoring, enabling individuals to collect samples at home for analysis. At-home cancer testing enables early detection of cancer, which means more treatment options and less extensive treatment, thus leading to higher chances of survival. By using IVD technologies for early detection, rapid point-of-care and at-home testing can be provided to potential patients. Furthermore, advancements in PoC testing technology make at-home testing more accessible and common. People seeking a convenient and accessible way to monitor are contributing to driving the demand for at-home cancer testing that can be performed outside clinical settings. Furthermore, the integration of mobile applications with testing kits enables users to track prompts for follow-up tests and thereby consult healthcare professionals from home.  

The global market share is anticipated to be supported by expanding R&D efforts by major industry participants, including Exact Sciences, Guardant Health, Freenome, and others, for improving the testing platforms. There are opportunities in the developing market due to the increasing technological advancements in molecular diagnostics and AI. For instance, in October 2024, Prenetics Global Ltd. announced Tencent’s US$30 million investment in Insighta, strengthening a strategic partnership for AI-driven early cancer detection.

Key Market Insights

• North America is expected to account for the largest share in the At-Home Cancer Testing Market during the forecast period.
• In terms of sample type, the blood sample segment is projected to lead the At-Home Cancer Testing Market with a major share throughout the forecast period
• In terms of cancer type, the colon and breast cancer segment accounts for the leading share in the at-home cancer testing market
• In terms of test type, the genetic testing segment captured the largest portion of the market

At-Home Cancer Testing Market Trends

• Rapid growth of blood-based liquid biopsy kits for early detection of cancer biomarkers
• Adoption of advanced technologies, including AI, machine learning, genomics, and proteomics
• Development of new specific cancer screening kits for cancer detection
• Increasing emphasis on DNA and HPV testing

Report Coverage

This research report categorizes the at-home cancer testing market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyzes the key growth drivers, opportunities, and challenges influencing the at-home cancer testing market. Recent market developments and competitive strategies, such as expansion, type launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyzes their core competencies in each sub-segment of the at-home cancer testing market.

Driving factors

With the growing prevalence of cancers, an increasing demand for providing efficient methods for detecting cancer at early stages is driving the market demand for at-home cancer testing. Cancer is the leading cause of death worldwide, with an estimated 19.3 million new cases and 10 million deaths due to cancer. Additionally, an increasing awareness about health and well-being via public health campaigns with increased emphasis on preventive healthcare is contributing to propel the market for at-home cancer testing.

Restraining Factor

Factors restraining the at-home cancer testing market are the increased costs of cancer testing and kits. Further, issues regarding the test accuracy and reliability of the at-home cancer testing is hampering the market demand.

Market Segmentation 

The global at-home cancer testing market is divided into sample type, cancer type, and test type.

Global At-Home Cancer Testing Market, By Sample Type:

• The blood sample type segment dominated the market with a major share in 2024 and is projected to grow at a substantial CAGR during the forecast period.   

Based on sample type, the global at-home cancer testing market is segmented into blood sample, saliva sample, urine sample, and tissue sample. Among these, the blood sample type segment dominated the market with a major share in 2024 and is projected to grow at a substantial CAGR during the forecast period. Blood tests are a strong option for early cancer detection, especially prostate and breast cancer. It measures the elevated level of markers and genetic mutations. The increased use of blood samples among consumers due to their effectiveness in detecting various malignancies is driving the market.

The saliva segment is anticipated to grow at a significant CAGR during the forecast period, owing to its increased accessibility and user friendliness. Salivary sialic acid is considered a valuable tool for early cancer screening, especially for oral and breast cancers.

Global At-Home Cancer Testing Market, By Cancer Type:

• The colon cancer segment accounted for the dominant market share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on cancer type, the global at-home cancer testing market is segmented into colon cancer, breast cancer, prostate cancer, blood cancer, and others. Among these, the colon cancer segment accounted for the dominant market share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. At home, colon cancer tests, including guaiac fecal occult blood test, fecal immunochemical test, and multitarget stool DNA test, are used for screening for the signs of colorectal cancer. The increasing prevalence of colon cancer, with increasing technological advancements and early diagnostic initiatives, is promoting the market in the colon cancer segment.

The breast segment is anticipated to grow at a significant CAGR during the forecast period, driven by growing awareness of breast self-examination. There is increasing awareness about the early diagnosis of breast cancer with the implementation of screening initiatives by the government and health organizations.

Global At-Home Cancer Testing Market, By Test Type:

• The genetic testing segment dominated the at-home cancer testing market in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on test type, the global at-home cancer testing market is segmented into genetic testing, biomarker testing, immunological testing, and cell-free DNA testing. Among these, the genetic testing segment dominated the at-home cancer testing market in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The capacity of genetic testing to provide the critical hereditary cancer risk information is driving the at-home cancer testing market. Genetic tests help in detecting hereditary genetic mutations, which may be responsible for causing cancer.

The biomarker testing segment is anticipated to grow at a significant CAGR during the projected period, owing to its ability to determine the prognosis of cancer patients. Biomarker testing involves the analysis of genes, proteins, or other substances in body fluids for identifying specific markers associated with cancer.

Regional Segment Analysis of the Global At-Home Cancer Testing Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America At-Home Cancer Testing Market Trends

North America is expected to hold the largest share of the global At-Home Cancer Testing Market over the forecast period.

The North American region's supremacy includes the increased adoption of telehealth, remote patient monitoring, and technological advancements for more accurate and user-friendly at-home tests. Further, the increased awareness about cancer risk, along with advancements in diagnostic technologies, is propelling the at-home cancer testing market.

U.S. At-Home Cancer Testing Market Trends

The increasing adoption of at-home cancer testing kits, along with an increasing technological progress within connected health devices & digital diagnostic tools, is driving the market growth. Further, an increasing demand for early cancer detection due to consumer increased awareness, is contributing to propel the market demand.

Asia Pacific At-Home Cancer Testing Market Trends

Asia Pacific is expected to grow at the fastest CAGR in the At-Home Cancer Testing Market during the forecast period. In the Asia Pacific market, the growing prevalence of cancer, along with an increasing adoption of international digital health approaches, is propelling the market growth for at-home cancer testing. Further, the increasing emphasis on collaborations and partnerships for developing novel instruments is promoting the market of at-home cancer testing.

China At-Home Cancer Testing Market Trends

China is positioned as the leading share in the Asia Pacific at-home cancer testing market, due to an increasing awareness about early cancer detection and the increasing burden of chronic diseases. Further, government support for early cancer detection and adoption of telemedicine are promoting the market growth.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global at-home cancer testing market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

Worldwide Top Key Players In The At-Home Cancer Testing Market Include

• 23andMe
• PathAI
• Guardant Health
• Egenomics
• Quanterix
• NantHealth
• Oncocyte
• Genomic Health
• Exact Sciences
• Myriad Genetics
• Freenome
• Invitae
• CancerIQ
• GRAIL
• Thermo Fisher Scientific
• Others  

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent development

• In September 2025, Myriad Genetics, a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS, an AI technology company transforming precision medicine, announced a strategic collaboration to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test.
• In September 2025, Healthmine, a leading member engagement and rewards platform for health plans, announced a partnership with Exact Sciences, a global leader in cancer diagnostics, to improve colorectal cancer screening completion rates.

Market Segment

This study forecasts revenue at the global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the At-Home Cancer Testing Market based on the following segments:

Global At-Home Cancer Testing Market, By Sample Type

• Blood Sample
• Saliva Sample
• Urine Sample
• Tissue Sample

Global At-Home Cancer Testing Market, By Cancer Type

• Colon Cancer
• Breast Cancer
• Prostate Cancer
• Blood Cancer
• Others

Global At-Home Cancer Testing Market, By Test Type

• Genetic Testing
• Biomarker Testing
• Immunological Testing
• Cell-Free DNA Testing

Global At-Home Cancer Testing Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa